Breast Cancer Clinical Trial
Official title:
Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer
Regional lymph node status is the most important prognostic factor for disease-free and
overall survival in breast cancer. Accurate nodal staging can be achieved only by surgery.
Today, in early-stage invasive breast cancers with clinically negative lymph nodes,
minimally invasive sentinel lymph node biopsy (SLNB) is considered the gold standard of
regional lymph node staging. To optimize the effectiveness of SLNB, precise pre-and
intraoperative mapping of lymphatic drainage is important. The (SLNB) technique is not
standardized. The most common and most accurate way of lymphatic mapping is performed with
the combined application of a gamma-emitting isotope labeled substance and blue dye, the
so-called double labeling technique. Functional lymphatic drainage of SLNB double staining
in the mammary gland, skin and axilla present a number of uncertainties.
According to the axillary, lateral thoracic and thoracodorsal veins, Ibusuki et al. divided
the axillary region into four subregions: brachial (lateral), pectoral (anterior), central
and subscapular (posterior) zones. They revealed clear relationship between the anatomic
location and status of the SLN, also confirmed by Gallowitsch et al. SLN was detected in
Level I in 96% and in Level II in 4% by SPECT/CT.
Knowedge of relationships between the drainage of sentinel lymph node staining into the
axillary subregions, location of the primary tumor, tumor size, SLN positivity and its
location within the subregion are of particular importance in the decision making whether or
not axillary lymphadenectomy (ALND) needs to be performed.
In the prospective randomized phase 3 trial by Giuliano et al. (ACOSOG Z-11) ALND was not
performed in early breast cancer patients with clinically negative axilla and
breast-conserving surgery, for 1-2 macroscopically positive SLNs (10). After an average
follow-up of 6.3 years, data were compared to the traditional ALND group and no difference
was detected in 5-year overall survival or disease-free survival at 5 years.
Aims of the investigation:
To examine the location of SLN in the axillary subregion (anterior, posterior, central,
lateral, apical) in patients with early breast cancer (T <5 cm).
To statistically assess correlations between the location, size, histological parameters of
primary breast tumor and the subregion of the SLN.
To statistically assess SLN positivity and its location within the sbregion.
To statistically assess subregional localisation of positive SLN and the number of all
positive regional lymph nodes, to predict a limited number of cases with lymph node
metastasis, based on the test results of the ACOSOG Z-11 trial, by which ALND could be
omitted.
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |